Company Overview and News
Wolf Minerals Ltd (LON:WLFE) said it has settled a dispute with GR Engineering over a contract for the Hemerdon tungsten and tin project.
Wolf Minerals Ltd (LON:WLFE) operates one of the world’s major tungsten mines at Drakelands in the southwest of England.
Wolf Minerals (LON:WLFE) reported interim results revealing narrower losses, thanks in part to higher revenues generated by its tungsten mine in Devon.
Devon-based tungsten and tin miner Wolf Minerals Limited (LON:WLFE) has topped up its bridge loan facility with major shareholder Resource Capital and restructured its other Senior debts.
Wolf Minerals Ltd (ASX: WLF)(LON: WLFE) has released a quarterly update in regard to operations at its Drakelands tungsten mine in Devon, England.
Wolf Minerals (LON:WLFE) (ASX:WLFE) has issused shares to its non executive directors as part of their fees for the fourh quarter of 2017.
Any investor keen to participate in the recent base metal revival could do worse than look at tin, which has been overshadowed recently by rivals zinc and copper.
Wolf Minerals Limited (LON:WLFE) (ASX:WLF) has received a £10mln boost to its short term working capital as it progresses towards long term self-sustaining operations at the Drakelands open pit mine in south-west England.
Wolf Minerals (LON:WLFE)(ASX:WLF) has been granted permission by the Australian Securities Exchange to allot security over the Hemerdon tungsten mine in Devon in return for an increase in the bridge loan facility provided by major investor Resource Capital Funds.
Following on from reports in early October regarding an 18 per cent pre-tax loss for the Anglo-Australian tungsten producer Wolf Minerals in the 2018 financial year, the company has released a report detailing a £10 million ($17.1 million) cash boost for its flagship Drakelands mine in Devon, England.
Wolf Minerals Limited (LON:WLFE) (ASX:WLF) has got a £10mln boost to its short term working capital as it progresses towards long term self-sustaining operations at the Drakelands open pit mine in south-west England.
Anglo-Australian tungsten producer Wolf Minerals has seen an 18 per cent rise in pre-tax losses for its Drakelands Mine in County Devon, England.
Wolf Minerals, the operator of one of the few active mines in the UK, said it has been encouraged by improvements in the tungsten market despite losses widening by 18pc in the last year.
Tin explorer Kasbah Resources has recruited former Wolf Minerals boss Russell Clark as its new chief executive.
My last post mentioned me selling out of Woodford Income fund and going it alone in an attempt to lose money in a more amusing manner than Woodford had. Which primarily involved shorting EURGBP and owning a small Tungsten mining stock called Wolf Minerals (OTCPK:WFMRF). The bad news is that Woodford outperformed me on the losing money stakes, whilst the good news is I can now afford a craft ale and I had some fun.
2018-05-21 - Asif
Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...
2018-05-21 - Asif
Business Agenus is a clinical-stage immuno-oncology (“I-O”) company dedicated to becoming a leader in the discovery and development of innovative combination therapies and committed to bringing effective medicines to patients with cancer. The company's business is designed to drive success in I-O through speed, innovation, and effective combination therapies. Agenus has assembled fully integrated capabilities from novel target discovery, antibody generation, cell line development, and good manufacturing practice (“GMP”) manufacturing together with a comprehensive portfolio consisting of antibody-based therapeutics, adjuvants and cancer vaccine platforms. The company leverage its immune biology platforms to identify effective combination therapies for development and have developed productive partnerships to advance its innovation. The company believe the next generation of cancer treatment will build on clinically validated antibodies targeting CTLA-4 and PD-1 combined wi...
2018-05-21 - Asif
Business The company started Square in February 2009 to enable businesses (sellers) to accept card payments, an important capability that was previously inaccessible to many businesses. However, sellers also need innovative solutions to thrive, and Square has since expanded to provide additional products and services to give these businesses access to the same tools as large businesses. This approach aligns with its purpose of economic empowerment, as everything the company do should give sellers accessible, affordable tools to grow their businesses and participate in the economy. Square is a cohesive commerce ecosystem that helps its sellers start, run, and grow their businesses. The company combine sophisticated software with affordable hardware to enable sellers to turn mobile and computing devices into powerful payment and point-of-sale solutions. Square has high seller acceptance rates and fast onboarding, while maintaining low risk and fraud losses as a result of its a...